| Objective Cardiovascular diseases, in particular coronary heart disease (CHD), are one of the most frequent causes of death worldwide. They are now particularly common in developed countries. The main aim of the treatment of CHD is to alleviate the symptoms, improve the quality of life and also the prognosis by preventing myocardial infarction and death. According to the latest European Cardiology Society guidelines, the pharmacological treatment of CHD includes three groups of well known anti-anginal agents with a haemodynamic mode of action i.e. nitrates, 6-blockers and calcium antagonists. A new group of drugs called metabolic modulators has recently aroused much interest. Trimetazidine (TMZ), one of these, is a metabolic anti-ischaemic agent that has been shown to preserve energy balance, but there are still controversies about the drug. The aim of this study was to evaluate the effects of add-on treatment with TMZ on certain clinical parameters of CHD patients with angina pectoris, already receiving optimal standard antianginal therapy. Methods This study was done on 31 patients already diagnosed as CHD and having angina pectoris. Some of them were hospitalized during the study period and the rest were followed up in the out patient department. Patients aged 61± 9.2 years took part in the study. Out of the total number of patients (n=31), 3 (9.7%) were women. 12 (38.7%) patients had old myocardial infarction (OMI) with unstable angina (UA) and 16 (51.9 %) had UA alone. 5 (16.1%) patients had done coronary angiography but without stenting. 3 (9.6%) patients had undergone percutaneous coronary intervention (PCI) with stenting more than 6 months previously and having UA at the time of the... |
PDF Full Text Request